Business Wire

Cedo Drives Green Agenda With New Group Sustainability Director

Share

Cedo, one of Europe’s largest manufacturers of private label consumer products for waste disposal, food preparation and storage, has appointed its first Group Sustainability Director. The role will be crucial in maintaining a consistent focus on one of Cedo’s core values, to foster sustainability in all aspects of its business activity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230306005006/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Martin Burdekin, Group Sustainability Director, Cedo (Photo: Business Wire)

Martin Burdekin, currently UK Commercial Director, is moving to this new role, where he will lead the further development and implementation of Cedo’s sustainability strategy across Cedo’s global operations which span the UK, Europe and Asia. Martin will become a member of the executive leadership team, reporting directly to CEO Thierry Navarre.

Burdekin said: “I am tremendously excited to have the opportunity to build upon Cedo’s heritage of sustainability by leading the development and roll-out of our sustainability Strategy. Responding proactively to a changing legislative landscape and customer ESG requirements has been a big part of my commercial role since I joined Cedo, and I look forward to working with my colleagues and our partners in helping make a positive difference to people’s lives.”

Thiery Navarre, CEO of Cedo, commented: “Since joining Cedo, Martin has consistently proven his passion for driving the sustainability agenda. His expertise and passion will help us build Cedo to be recognised as best-in-class when it comes to sustainability.”

For more than 50 years, Cedo has manufactured and supplied Europe’s leading retailers with waste collection bags as well as products designed to protect, store and preserve food, helping to reduce waste. Cedo also pioneers breakthroughs in innovation, for example creating the UK’s first antibacterial recycled refuse sack for retail in 2021.

Cedo has more than 2,000 employees across seven sites in Europe and the Far East, with a turnover of more than €500m. The company serves 30,000 customers within the European retail and B2B sector and operates its own recycling centre in Holland, which has become one of the largest flexible film recycling centres in Europe. It is also a member of the Ellen MacArthur Foundation’s New Plastics Economy.

About Cedo

Established in 1965, is one of Europe's largest and most sustainable suppliers of refuse sacks made from recycled plastics, as well as other consumer household products designed to protect and store food. For more than thirty years it has led the development of recycling mixed plastic film recovered from households to give more plastic a second life, creating 100% recycled and 100% recyclable products designed to keep European households, workplaces and leisure spaces clean, healthy and safe.

For further information and to request visuals or interviews please contact Miki Haines-Sanger at Golden Goose Communications on +44 7 900 690 574 / miki@goldengoosepr.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Miki Haines-Sanger
Golden Goose Communications
+44 7 900 690 574
miki@goldengoosepr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye